title: Immunohistochemical Predictors of Bone Metastases in Breast Cancer Patients.
abstract: Bones are the most common metastatic site of relapse in breast cancer patients and the prediction of bone metastases (BM) risk might prompt developing preventive and therapeutic strategies. The aim of the study was to correlate immunohistochemical (IHC) expression of selected proteins in primary breast cancer with the occurrence of BM. We analyzed expression of proteins potentially associated with BM in primary tumors of 184 patients with metastatic breast cancer (113 with- and 71 without BM). Expression of estrogen receptor (ER) in primary tumor was more common in patients with- compared to those without BM (74 vs. 45 % respectively, p = 0.0001), whereas in this subset less common was expression of parathyroid hormone related protein receptor type 1 (16 vs. 34 %, respectively, p = 0.007) and cytoplasmic expression of osteopontin (OPNcyt; 1.9 vs. 14 %, respectively, p = 0.002). The relationship between expression of ER and OPNcyt and the occurrence of BM was confirmed in the multivariate analysis. The ER-positive/OPNcyt negative phenotype was significantly more common in patients with- compared to those without BM (75 and 25 %, p < 0.0001, respectively; HR 1.79, p = 0.013). Luminal A (43 vs. 23 % respectively, p = 0.009) and luminal B/HER2-positive (16 vs. 4.9 % respectively, p = 0.032) subtypes were more common in patients with- compared to those without BM, whereas triple negative breast cancer subtype was less common (16 vs. 38 %, p = 0.002).
authors.affiliation: Medical University of Gdańsk, Gdańsk, Poland, pwinczura@gmail.com.
authors.forename: Piotr
authors.initials: P
authors.lastname: Winczura
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Sosińska-Mielcarek
authors.forename: Renata
authors.initials: R
authors.lastname: Duchnowska
authors.forename: Andrzej
authors.initials: A
authors.lastname: Badzio
authors.forename: Joanna
authors.initials: J
authors.lastname: Lakomy
authors.forename: Hanna
authors.initials: H
authors.lastname: Majewska
authors.forename: Rafał
authors.initials: R
authors.lastname: Pęksa
authors.forename: Beata
authors.initials: B
authors.lastname: Pieczyńska
authors.forename: Barbara
authors.initials: B
authors.lastname: Radecka
authors.forename: Sylwia
authors.initials: S
authors.lastname: Dębska-Szmich
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Adamowicz
authors.forename: Wojciech
authors.initials: W
authors.lastname: Biernat
authors.forename: Jacek
authors.initials: J
authors.lastname: Jassem
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001859:Bone Neoplasms / Q000378:metabolism / Q000473:pathology* / Q000556:secondary*; D001943:Breast Neoplasms / Q000378:metabolism / Q000473:pathology*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D008875:Middle Aged; D053495:Osteopontin / Q000378:metabolism; D044162:Parathyroid Hormone-Related Protein / Q000378:metabolism; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism
chemical_list: D053495:Osteopontin; D044162:Parathyroid Hormone-Related Protein; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen